Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America.
Lupus is a devastating heterogeneous autoimmune disease affecting millions worldwide with symptoms that can range from debilitating fatigue to life-threatening organ damage. Lupus Therapeutics and the Lupus Research Alliance are committed to advancing the identification and accelerating the development of potential new treatments for a community in urgent need of more options.
The three trials will evaluate the effectiveness and safety of ianalumab compared to placebo given as a subcutaneous injection once a month or every three months. All the three trials are already underway and enrolling lupus patients.
We believe this collaboration between Lupus Therapeutics and Novartis Pharmaceuticals will provide a significant opportunity to accelerate the development of new treatments and therapies for both SLE and lupus nephritis conditions and are hopeful that this collaboration will pave the way for improved patient outcomes."
Lupus Therapeutics Executive Vice President Stacie Bell, Ph.D.
Click below to learn more about each trial.
Gut health and diet: Keys to treating acne, alopecia, and dermatitis